Valneva SE (VALN)

CIK 0001836564 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —
FY-2022

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
—
Audit Information
—
Statements
Consolidated Statement of Profit Or Loss
—
Consolidated Statement of Comprehensive Income
—
Consolidated Statement of Financial Position
—
Consolidated Statement of Cash Flows
—
Consolidated Statement of Cash Flows (P)
—
Consolidated Statement of Changes In Equity
—
Notes
Assets Classified As Held For Sale
—
Borrowings
—
Cash and Cash Equivalents
—
Cash Flow Information
—
Commitments and Contingencies
—
Contract Liabilities
—
Critical Accounting Judgements and Key Sources of Estimation Uncertainty
—
Cybersecurity Risk Management and Strategy Disclosure
—
Earnings (losses) Per Share
—
Employee Benefit Expense
—
Equity
—
Events After The Reporting Period
—
Expenses By Nature
—
Finance Income/(expenses), Net
—
Financial Instruments
—
General Information
—
Impairment Testing
—
Income Tax Benefit/(expense)
—
Income Tax Income/(expense)
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Inventories
—
Lease Liabilities
—
Leases (right of Use Assets)
—
Other Assets
—
Other Income/(expenses), Net
—
Other Liabilities
—
Property, Plant and Equipment
—
Provisions
—
Refund Liabilities
—
Related-party Transactions
—
Revenues
—
Segment Information
—
Share-based Compensation
—
Summary of Significant Accounting Policies
—
Tax and Employee-related Liabilities
—
Trade Payables and Accruals
—
Trade Receivables
—